Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended Jun... (AP measures to their most closelyapplica...)

Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008

Date:8/6/2008

AP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Below is a reconciliation of adjusted net earnings available to common shareholders and adjusted diluted EPS to GAAP net (loss) earnings available to common shareholders and diluted GAAP EPS:

Three months Three months

ended ended

($'s in millions except per

share amounts) June 30, 2008 June 30, 2007

GAAP net (loss) earnings available

to common shareholders & diluted

GAAP EPS $(8.4) $(0.03) $79.7 $0.32

Purchase accounting related

amortization (1) 112.1 18.8

Specialty Segment profitability (19.7) -

Loss on foreign currency contract - 57.5

Bystolic revenue (9.8) -

Integration and other non-recurring

expenses (2) 35.8 -

Tax effect of the above items (3) (62.4) (27.1)

Adjusted net earnings available to

common shareholders and adjusted

diluted EPS $47.6 $0.16 $128.9 $0.52

(1) The three months ended June 30, 2008 include amortization expense related to purchased intangible assets as well as amortization of the inventory step-up related to Merck Generics. The three months ended June 30, 2007 include amortization expense related to purchased intangible assets as well as amortization of the inventory step-up related to Matrix.

(2) The three months ended June 30, 2008, include non-recurring expenses principally relate
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.

Post Your Comments:

(Date:5/24/2013)... Compromise is often cited as crucial for relationships, ... sleep and comfort. However, many couples find themselves facing dilemmas ... this can cause added stress, lost sleep, and some resentment. ... common issues in their latest article on the subject. ... What to do When You Disagree on the Best Mattress ...

(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... the 2010 DePuy hip recall continue to move forward ... According to documents filed in California’s San Francisco ... been seeking an expedited trial of her DePuy hip ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. CGC11508806; ...

(Date:5/24/2013)... 24, 2013 KC and Monica Craichy, Founders ... for FreeRide836. Their oldest sons, Kyle and Austin Craichy, will ... family and several professional kiteboarders. , KC Craichy said he ... has miraculously come together such that virtually everyone who planned ... , 20 kite boarders will meet at Matheson Hammock Park ...

(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...

(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...

Breaking Medicine News(10 mins):Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3

[0] What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples [0] DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case [0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 [0] Multiple research teams unable to confirm high-profile Alzheimer's study

... Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates ... , NEW YORK, June 19, 2009 Forest Laboratories, ... from two global multi-center Phase III studies of ceftaroline for ... data in each of the pivotal trials (FOCUS I and ...

... Kenneth A. May, former CEO of FedEx Kinko,s, has been ... Dimes, it was announced today. , , "Ken May is ... Prematurity Campaign," said Dr. Jennifer L. Howse, President of the March ... work towards our goal of giving every baby a healthy start ...

... changes , FRIDAY, June 19 (HealthDay News) -- A key ... by British researchers, who suggest that their finding may lead ... King,s College London and Imperial College London helps explain why ... are remodeled and how these changes contribute to chronic asthma. ...

... The Center for Laser Surgery, Washington, DC has announced the ... recently FDA approved, is the first cosmetic neurotoxin available alongside ... The Center for Laser Surgery was ... Dysport. As Washington, DC, Maryland and Virginia,s largest and most ...

... , WASHINGTON, June 19 The Department of Veterans Affairs ... its award-winning health care system, is poised to welcome nearly ... the country by expanding access to health care enrollment for ... , , "This incremental approach to expanding enrollment ensures ...

... should be treated as a priority if offenders held in ... research from the University of Adelaide, Australia. Adelaide researchers ... health of young offenders undertaken in the USA, UK, Europe ... have been published in this month,s Australian Journal of ...

Cached Medicine News:Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5 Health News:Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative 2 Health News:VA Reopening Health Care Enrollment to Thousands of Veterans 2 Health News:Young offenders' health critical to rehabilitation 2 Health News:Young offenders' health critical to rehabilitation 3

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization Ken May Re-Elected for Second Term as Chairman of the Board of March of Dimes Asthma Discovery May Lead to Better Treatments Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative VA Reopening Health Care Enrollment to Thousands of Veterans Young offenders' health critical to rehabilitation

(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013. More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...

(Date:5/24/2013)... , May 24, 2013 Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

[0] Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg [0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... Amgen (Nasdaq: AMGN ) today announced results ... treatment for advanced cancer patients with bone metastases in ... (zoledronic acid). These results underscore the efficacy profile of ... bone metastases from advanced breast cancer, as well as ...

... Dec. 10, 2010 Syndax Pharmaceuticals, Inc., a clinical-stage ... on entinostat, an orally bioavailable, highly selective, class I ... cancer. The data are being presented as oral poster ... 8 through December 12 in San Antonio Texas. ...

Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer

The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....

... accelerators are true high-performance ... multileaf collimation and electronic ... enable you to perform ... IMRT treatments, as well ...

... Clinac EX accelerators ... with integrated Varian multileaf ... imaging systems which enable ... most advanced computer-driven IMRT ...

The Clinac C family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....

Medicine Products:

Primus Linear Accelerator Clinac 23EX Clinac 21EX Clinac C